Join to View Full Profile
550 1st AvenueNew York, NY 10016
Dr. Mehnert is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rutgers Robert Wood Johnson Medical SchoolClass of 2001
Certifications & Licensure
NY State Medical License 2002 - 2025
NJ State Medical License 2007 - 2021
American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors Start of enrollment: 2021 Jun 15
Roles: Contact
Publications & Presentations
PubMed
- 1 citationsOutcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.Eleanor E Handel, Janet McKeown, Joe Wei, Roma A Kankaria, Hannah Burnette
European Journal of Cancer. 2025-01-17 - 4 citationsA phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, ...Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults
Journal of the American Academy of Dermatology. 2025-01-01 - Evolution of Rapid Clonal Dynamics and Non-Cross-Resistance in Response to Alternating Targeted Therapy and Chemotherapy in BRAF-V600E-Mutant Colon Cancer.Srilatha Simhadri, Jillian N Carrick, Susan Murphy, Om A Kothari, Husam Al-Hraishami
JCO Precision Oncology. 2024-12-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
